How many studies have been conducted on Rosiglitazone?

BiohacksAI has indexed 297 PubMed studies on Rosiglitazone, including 40 randomized controlled trials (RCTs). 41% of studies involve human subjects.

What are the main research areas for Rosiglitazone?

The primary research domains for Rosiglitazone are 🔥 Metabolic, 🔬 Oncology, 🧬 Hormones. This is based on analysis of 297 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Rosiglitazone

A thiazolidinedione that functions as a selective agonist for PPAR GAMMA. It improves INSULIN SENSITIVITY in adipose tissue, skeletal muscle, and the liver of patients with TYPE 2 DIABETES MELLITUS.

297+ PubMed studies analyzed · 40 RCTs · Evidence Score: 47.9

Research Domains

Rosiglitazone has been studied across 27 research domains including 🔥 Metabolic, 🔬 Oncology, 🧬 Hormones, 🔬 Inflammation, ❤️ Cardiovascular. The primary research focus is 🔥 Metabolic with 62% of studies addressing this area.

Loading evidence profile...

This evidence profile for Rosiglitazone is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.